Paper Details

  1. Home
  2. Paper Details

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

Author: , AndersenJanet, AsmelashAida, HakimJames, HavlirDiane V, HoggEvelyn, HosseinipourMina C, IvePrudence, KendallMichelle A, KumarasamyN, KumwendaJohnstone, LallooUmesh, LamaJavier R, LuetkemeyerAnne F, MohapiLerato, MokoEvans, MugyenyiPeter, PadayatchiNesri, PapeJean W, QasbaSarojini S, ReidStewart, RooneyJames F, SanchezAlejandro, SanchezJorge, SanneIan, SantosBreno R, SaweFred, SomeFatuma F, SwindellsSusan, VelosoValdilea G, WuXingye

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Earlier ART did not reduce the rate of new AIDS-defining illness and death, as compared with later ART. In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known. METHO...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22010914

データ提供：米国国立医学図書館（NLM）

Timing is Key: Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

The fight against [HIV/AIDS] and tuberculosis (TB) is a complex endeavor, requiring carefully coordinated treatment strategies. This research delves into the optimal timing for initiating antiretroviral therapy (ART) in HIV-1 infected individuals with TB, a crucial aspect of managing this dual infection. The study examines the impact of earlier ART initiation (within 2 weeks of TB treatment) versus later initiation (between 8 and 12 weeks after TB treatment) on patient outcomes. The research provides valuable insights into the intricate interplay between ART, TB treatment, and the immune status of HIV-1 infected individuals.

Earlier ART: A Potential Advantage in Specific Cases

This research sheds light on the potential benefits of earlier ART initiation in specific cases of HIV-1 infection and TB. The study found that, while overall earlier ART did not significantly reduce the risk of new AIDS-defining illnesses and death, it did show a positive effect in patients with a baseline CD4+ T-cell count of less than 50 per cubic millimeter. This finding suggests that earlier ART initiation may be particularly beneficial for individuals with severe immune compromise.

Navigating the Complexities: Balancing Risks and Benefits

The research highlights the complex interplay between ART, TB treatment, and the immune status of HIV-1 infected individuals. The study emphasizes that earlier ART initiation may come with an increased risk of tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). This finding reinforces the need for a careful assessment of individual patient characteristics and risks when making treatment decisions.

Dr.Camel's Conclusion

This research, like the desert wind, reveals the dynamic nature of HIV-1 infection and TB co-infection. The study underscores the importance of individualizing treatment approaches, taking into account the patient's immune status and potential risks. By carefully navigating the timing of ART initiation, we can enhance patient outcomes and improve the management of these challenging conditions.

Date :
  1. Date Completed 2011-11-02
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

22010914

DOI: Digital Object Identifier

NIHMS367018

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.